halopemide
halopemide structure
|
Common Name | halopemide | ||
|---|---|---|---|---|
| CAS Number | 59831-65-1 | Molecular Weight | 416.876 | |
| Density | 1.3±0.1 g/cm3 | Boiling Point | N/A | |
| Molecular Formula | C21H22ClFN4O2 | Melting Point | N/A | |
| MSDS | Chinese USA | Flash Point | N/A | |
| Symbol |
GHS07 |
Signal Word | Warning | |
Use of halopemideHalopemide is a potent phospholipase D (PLD) inhibitor, with IC50s of 220 and 310 nM for human PLD1 and PLD2, respectively. Halopemid is a dopamine receptors antagonist, and acts a psychotropic agent[1][2]. |
| Name | N-[2-[4-(5-chloro-2-oxo-3H-benzimidazol-1-yl)piperidin-1-yl]ethyl]-4-fluorobenzamide |
|---|---|
| Synonym | More Synonyms |
| Description | Halopemide is a potent phospholipase D (PLD) inhibitor, with IC50s of 220 and 310 nM for human PLD1 and PLD2, respectively. Halopemid is a dopamine receptors antagonist, and acts a psychotropic agent[1][2]. |
|---|---|
| Related Catalog | |
| Target |
PLD1:220 nM (IC50) PLD2:310 nM (IC50) dopamine receptors |
| In Vitro | Halopemide (1-2 μM; 21 day) affects calcification in transdifferentiated MOVAS cells[3]. |
| In Vivo | Halopemide (10 mg/kg; p.o.) induces dyskinesias in the majority of monkeys tested[2]. |
| References |
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Molecular Formula | C21H22ClFN4O2 |
| Molecular Weight | 416.876 |
| Exact Mass | 416.141541 |
| PSA | 70.13000 |
| LogP | 4.47 |
| Index of Refraction | 1.612 |
| Storage condition | 2-8°C |
|
CAY10593 inhibits the human P2X7 receptor independently of phospholipase D1 stimulation.
Purinergic Signal. 9(4) , 609-19, (2013) The P2X7 receptor is a trimeric ATP-gated cation channel important in health and disease. We have observed that the specific phospholipase D (PLD)1 antagonist, CAY10593 impairs P2X7-induced shedding o... |
|
|
Halopemide, a new psychotropic agent. Cerebral distribution and receptor interactions.
Pharm. Weekbl. Sci. 7(1) , 1-9, (1985) Halopemide is a new psychotropic agent, a structural analogue of the neuroleptics of the butyrophenone type but with different pharmacological and clinical properties. Preliminary clinical findings in... |
|
|
Dynamic cation-exchange systems for the separation of drugs derived from butyrophenone and diphenylpiperidine by high-performance liquid chromatography and applied in the determination of halopemide in plasma.
J. Chromatogr. A. 164(2) , 177-85, (1979) Dynamic (solvent generated) cation-exchange systems for the separation of drugs and main metabolites derived from butyrophenone and diphenylpiperidine (haloperidol, pimozide, halopemide) were investig... |
| halopemide ( N-<2-<4-(5-chloro-2-oxo-1-benzimidazolinyl)piperidino>ethyl>-p-fluorobenzamide ) |
| Halopemidum |
| Halopemida |
| N-{2-[4-(5-Chloro-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)-1-piperidinyl]ethyl}-4-fluorobenzamide |
| N-(2-(4-(5-Chloro-2-oxo-1-benzimidazolinyl)piperidino)ethyl)-p-fluorobenzamide |
| 5-chloro-1-{1-[2-(4-fluoro-benzoylamino)-ethyl]-piperidin-4-yl}-1,3-dihydro-benzoimidazol-2-one |
| N-2-[4-(5-chloro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]ethyl-4-fluoro benzamide |
| N-{2-[4-(5-Chloro-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidin-1-yl]ethyl}-4-fluorobenzamide |
| R 34,301 |
| Benzamide, N-[2-[4-(5-chloro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]ethyl]-4-fluoro- |
| halopemide |
| Halopemide (USAN/INN) |
| N-[2-[4-(5-Chloro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]ethyl]-4-fluorobenzamide |